A Phase 1/2 interventional study of AAV8.hLCA5 in LCA5, sponsored by Opus Genetics, Inc. Recruiting at 2 sites in United States. Open to participants aged 4 Years and older. Per ClinicalTrials.gov, last updated 2026-02-19.
Sponsored by Opus Genetics, Inc · Phase 1/2, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 84 studies in Retinal Degeneration with a site in United States — 11 open to participants now, 29 under way, 3 of them phase 3. Retinal Degeneration · United States.
Among the 84 studies in Retinal Degeneration with a site in United States, this one is the 47th largest by planned enrollment of the 62 interventional ones that give a count, is one of 11 that started in 2023, is one of 14 in phase 1/2, reaches primary completion later than 18 of the 26 other live ones, and was the 66th registered.
132 studies on the registry are indexed under Retinal Degeneration; 23 are open to participants now.
Browse Retinal Degeneration studies →11 of the 84 studies in Retinal Degeneration with a site in United States are open now. Recruiting first, the newest first:
University College, London · Sites in United States, Germany, United Kingdom
Ages up to 50 · Healthy volunteers
Washington University School of Medicine · Sites in United States
Ages 50+
BlueRock Therapeutics · Sites in United States
Ages 18+
Food and Drug Administration (FDA) · Sites in United States
Ages 21+
National Eye Institute (NEI) · Sites in United States
Ages 5–100 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 15 Retinal Degeneration studies recruiting now, 10 (67%) set no upper age limit and 3 (20%) stop at 75 or younger; 7 take children under 18; 5 take healthy volunteers.
This study: 4 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
84 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 33 · Phase 3 13 · Phase 4 2
First in 1978; this study’s year is marked. 11 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 22 is below the median of 40 across 98 interventional studies indexed under Retinal Degeneration.
Median enrollment 51 across the 62 interventional studies, 83 across the 21 observational. Of the 50 that completed or were terminated, 27 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
58 of 84 have an industry lead sponsor. The 10 most frequent:
Opus Genetics, Inc is the lead sponsor of 17 studies on the registry; 4 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 13 (100%) have results posted.
Opus Genetics, Inc has 1 study filed under Retinal Degeneration — fewer than ten, so there is no comparison to draw.
7 of the studies in Retinal Degeneration with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04704921Phase 3AbbViePivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD | 2026-12 |
| NCT05748873SparingVisionPromising ROd-cone DYstrophy Gene therapY | 2027-02 |
| NCT06167642Johns Hopkins UniversityRetinal Atrophy and Neurofilament Light Chain in People With Multiple Sclerosis Taking Ofatumumab | 2027-03 |
| NCT06048185Nanoscope Therapeutics Inc.Non-interventional Long Term Follow-up Study of Participants Previously Enrolled in the STARLIGHT Study | 2027-05 |
| NCT04765345Jaeb Center for Health ResearchRate of Progression of PCDH15-Related Retinal Degeneration in Usher Syndrome 1F | 2027-06-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 84 studies in Retinal Degeneration with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goals of this clinical trial are assess the natural course of LCA5-IRD over 6 months and to evaluate the safety and preliminary efficacy of subretinal gene therapy with OPGx-001 in patients with inherited retinal degeneration due to biallelic mutations in the LCA5 gene. Funding Source- FDA Office of Orphan Products Development (OOPD).
This is a non-randomized, open-label, phase 1/2 dose-escalation study evaluating untreated patients for 6 months and with three doses of OPGx-001 for the treatment of LCA5-IRD.
Enrollment will begin with a low-dose of OPGx-001 delivered via single, unilateral subretinal injection (Cohort 1) and proceed to an intermediate dose (Cohort 2) and subsequent high dose (Cohort 3). Escalation to each next cohort will proceed only after review of all data and upon recommendation by an independent data monitoring committee (IDMC).
Concurrently, 16 untreated patients will be assessed for 6 months prior to treatment to study the natural course of LCA5-IRD.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A single, unilateral, subretinal injection of low dose (1E10 vg/eye) OPGx-001 is injected into two LCA5 adults (18 yo or above) in a sentinel fashion. A 30-day safety evaluation and data committee review and approval of continued dosing occurs. If additional dosing is recommended, a subsequent LCA5 adolescent (13-17) may be treated in a sentinel fashion, with a unilateral, subretinal injection of OPGx-001. A 30-day safety evaluation and data committee review and approval of continued dosing occurs. If additional dosing is recommended, two remaining adolescents (13-17) are eligible to be treated with a single, unilateral, subretinal injection of a low dose of OPGx-001. Total cohort size is 5 (2 adults and 3 adolescents).
Biological: AAV8.hLCA5
A single, unilateral, subretinal injection of an intermediate dose (3E10 vg/eye) OPGx-001 is injected into two LCA5 adults (18 yo or above) in a sentinel fashion. A 30-day safety evaluation and data committee review and approval of continued dosing occurs. If additional dosing is recommended, a subsequent LCA5 adolescent (13-17) may be treated in a sentinel fashion, with a unilateral, subretinal injection of OPGx-001. A 30-day safety evaluation and data committee review and approval of continued dosing occurs. If additional dosing is recommended, two remaining adolescents (13-17) are eligible to be treated with a single, unilateral, subretinal injection of an intermediate dose of OPGx-001. Total cohort size is 5 (2 adults and 3 adolescents).
Biological: AAV8.hLCA5
A single, unilateral, subretinal injection of high dose (1E11 vg/eye) OPGx-001 is injected into two LCA5 adults (18 yo or above) in a sentinel fashion. A 30-day safety evaluation and data committee review and approval of continued dosing occurs. If additional dosing is recommended, a subsequent LCA5 adolescent (13-17) may be treated in a sentinel fashion, with a unilateral, subretinal injection of OPGx-001. A 30-day safety evaluation and data committee review and approval of continued dosing occurs. If additional dosing is recommended, two remaining adolescents (13-17) are eligible to be treated with a single, unilateral, subretinal injection of a high dose of OPGx-001. Total cohort size is 5 (2 adults and 3 adolescents).
Biological: AAV8.hLCA5
Part B will occur concurrently with Dose Groups 1-3. Sixteen patients will be assessed for 6 months to assess the natural course of LCA5-IRD, then will be treated with OPGx-001 which will be described in a future protocol amendment.
Adeno-associated virus vector expressing human LCA5 gene
Incidence of Dose Limiting Toxicities
Number of DLT events
Time frame: 2 years
Number of adverse events related to OPGx-001
Number of AEs related to IP
Time frame: 2 years
Incidence of adverse events related to OPGx-001
Incidence of AEs related to IP
Time frame: 2 years
Severity of adverse events related to OPGx-001
Severity of AEs related to IP
Time frame: 2 years
Number of procedure-related adverse events
Number of AEs related to IP administration
Time frame: 2 years
Incidence of procedure-related adverse events
Incidence of AEs related to IP administration
Time frame: 2 years
Severity of procedure-related adverse events
Severity of AEs related to IP administration
Time frame: 2 years
Assessment of cross-sectional spectral domain optical coherence tomography images
Qualitative Assessment of SD-OCT image
Time frame: 2 years
Assessment of Natural course of LCA5-IRD
Change from baseline in MLoMT
Time frame: 6 months
Assessment of Natural course of LCA5-IRD
Change from baseline in FST
Time frame: 6 months
Assessment of Natural course of LCA5-IRD
Change from baseline in BCVA
Time frame: 6 months
Assessment of Natural course of LCA5-IRD
Change from baseline in FCP/Microperimetry
Time frame: 6 months
Assessment of Natural course of LCA5-IRD
Change from baseline in SD-OCT
Time frame: 6 months
Assessment of Natural course of LCA5-IRD
Change from baseline in pupillometry
Time frame: 6 months
Assessment of Natural course of LCA5-IRD
Number of adverse events
Time frame: 6 months
Change from baseline over time in Multi-luminance Orientation and Mobility Test
Number of objects identified
Time frame: 2 years
Change from baseline over time in Dark-adapted full-field sensitivity testing
FST
Time frame: 2 years
Change from baseline over time in best corrected visual acuity (BCVA)
Measured using LogMAR scale
Time frame: 2 years
Change from baseline over time in visual functioning questionnaire
Assessed by the Modified National Eye Institute Visual Functioning Questionnaire
Time frame: 1 year
Microperimetry
Mean sensitivity, in dB
Time frame: 1 year
Kinetic perimetry
Field extent, in degrees
Time frame: 1 year
Virtual Reality Orientation and Mobility Test (VR-O&M)
Performance over a range of light levels
Time frame: 1 year
Frequency doubling technology (FDT) perimetry (sFDT-CA)
Time frame: 1 year
Light-adapted transient pupillary light reflex (LA-TPLR)
Time frame: 1 year
Sweep visual evoked potentials (sVEPs)
Time frame: 1 year
Chromatic referential looking
In dark-adapted patients
Time frame: 1 year
Full-field chromatic sensitivity testing (FST)
In free view
Time frame: 1 year
Portable chromatic pupillometry Portable chromatic pupillometry
Time frame: 1 year
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2023 (actual). Primary completion is estimated for Jun 2028, 60 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Opus Genetics, Inc